



NEWSLINE

A PUBLICATION OF THE COLLEGE ON PROBLEMS OF DRUG DEPENDENCE, INC.

Volume Thirteen, Number Three

• May 2009

CPDD President's Column

SHARON WALSH, Ph.D.

PRESIDENT

I last wrote this column in January after the Presidential election but before President Obama was inaugurated. Wow, so much has happened in this short time. The American Recovery and Reinvestment Act of 2009 (ARRA), designed to stimulate the flagging economy, became a reality on February 17th and changed the NIH landscape. The stimulus funding came fast and furious (a total of \$10.4 billion to NIH alone) with NIDA and the other agencies working at a frantic pace to keep up with daily announcements of funding plans, deadlines, reporting requirements and articulation of critical topics. This, of course, was felt close to home as well, with our institutional sponsored projects offices busily working to keep everyone informed and trying to stimulate faculty to vie for the various mechanisms with new names like Go Grants and Challenge Grants. It felt like everyone was quickly swept up in a grant-writing frenzy, with hopes that they would capitalize on this unexpected opportunity to capture some funding with a quick delivery deadline.

This was a dramatic shift from recent years where pay lines seemed to drop into the low single digits and A2 applications became the norm. In addition to producing the immediate benefit of job creation and job retention in our field, the ARRA has allowed NIDA and other NIH institutes to fund existing applications that were bound

and tied in the scientific equivalent of the religious place known as Limbo (Latin for edge or boundary)—those applications with good scores but not quite good enough to merit funding in these tight times (and teetering closely on the precipice of Hell). Hopefully, this infusion will not only stimulate the economy for the next two years but will have a more lasting impact by unplugging the clog in the funding pipeline, and allowing the pay line to rise up again.

Another unexpected consequence of our new national leadership was somewhat bittersweet. President Obama and Vice-President Joe Biden, both of whom vowed to have science inform policy, have appeared to recognize substance abuse for the public health problem that it truly is, by seeking to change the landscape at the highest level. They identified one of our very own, Dr. Tom McLellan, as their top candidate for Deputy Director of the Office of National Drug Control Policy. Unfortunately, Tom was our newly elected President-Elect for CPDD and with this new appointment would be unable to serve the College. While we were sad to see him step down, we are very pleased to have Tom, who is so passionate and committed (and outspoken), take on this leadership role. We feel confident that the core belief and values of CPDD regarding the critical importance of substance abuse research and treatment in improving lives will have a voice at the table

Continued on page 2

President’s Column *continued from page 1*

through Tom. We all wish him great success in this new role and smooth navigation through the federal system.

While I’m writing about the national front, just last week the Scientific Management Review Board, which was formed through the NIH Reform Act of 2006 and advises the NIH Director, met to discuss possible reorganization/consolidation of NIH institutes or centers. On the agenda was the consideration of a possible merger between NIDA and NIAAA into a single institute. Both Dr. Nora D. Volkow (Director of NIDA) and Dr. Kenneth Warren (Acting Director, NIAAA) spoke before the committee. The job of the committee was not to vote on a merger, but rather to make a yea or nay recommendation on whether further evaluation of the merger was worthy. Opinions vary widely on the merits of this potential merger; however, all parties seem to be in agreement that it would be harmful if a merger leads to a reduction in real resources to either drug or alcohol research communities. A thorough review

with input from interested and informed parties is expected to follow.

Bringing things closer to home, we are gearing up for our Annual Conference as June draws nearer. We have a full complement of the usual activities and events planned including special symposia, workshops, awards, posters, satellite meetings, training activities and fun (see the website for the meeting schedule). Dr. Nora Volkow will speak in the opening Plenary session, and Dr. Tom McLellan will be our featured speaker at the Public Policy Forum. It should be a great meeting and special thanks goes to Dr. Sari Izenwasser, Ellen Geller and the program committee members for their hard work in organizing the scientific content. Although Reno is a new venue and may sound titillating only if you are a gambler, staff at Sailair assure me that there are numerous local activities to entertain children and family if you plan to bring along non-scientists and non-gamblers to the meeting. Looking forward to seeing you all in Reno.

Newsline Contents	
Presidential Column	1
Special Events	2
2008 J. Michael Morrison Award	4
Airport Shuttle	8
Book Review	10
Editor’s Notes	14
Satellite Meetings at the CPDD 2009 Meeting	3, 6, 9, 12

CPDD Conference – Special Events

CPDD’s famous Brunch with Champions. This is a great opportunity for pre-docs, post-docs, and junior faculty to chat informally with senior investigators in the drug abuse research field. We highly encourage pre-registration because attendance will be limited. For the last four years, the brunch has filled early and we have had to turn away people who waited too long to register. The registration form can be downloaded from the CPDD web site: <http://www.cpdd.vcu.edu/>.

ASPET Mixer. You are invited to attend a special reception, hosted by the divisions of Behavioral Pharmacology and Neuropharmacology of the American Society for Pharmacology and Experimental Therapeutics (ASPET). Please be sure to stop by to learn about

ASPET and to network with fellow colleagues and friends from 6:30 to 8 PM on Sunday at the Poolside Terrace.

Trainee Mixer. Pre- and post-doc trainees are invited to a reception from 5:30 to 7 PM Monday in the Genoa room. This will be a wonderful time to mingle with other young investigators.

NIDA Tutorials. The 9th annual NIDA Tutorials are designed to provide junior investigators with fundamental information from a variety of disciplines representing the breadth of drug abuse and addiction research. The event will be held 1-5 PM Saturday in the Genoa room.

Grant-writing Workshop. The workshop will be held 1:30 to 5 PM Tuesday in the Genoa room. Registration for this event is closed.

2009 NIDA International Forum

Commonalities among the diseases of addiction:
implications for treatment and prevention

June 19–23 • Reno, Nevada

The National Institute on Drug Abuse (NIDA) International Program fosters international cooperative research and the exchange of scientific information by drug abuse researchers around the globe. The 2009 NIDA International Forum is scheduled for Friday and Saturday, June 19–23, 2009, in conjunction with the 71st Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD). The meeting will be held at John Ascuaga's Nugget Resort, Reno, Nevada

The topic for the 2009 NIDA International Forum is Commonalities Among the Diseases of Addiction: Implications for Treatment and Prevention. The Forum will feature a research symposium, interactive workshops, a poster session, and network-building activities highlighting NIDA-supported and other international research on drug abuse.

Highlights

- Practical Issues in Publishing Addiction Science
Chair: Robert L. Balster, Editor, Drug and Alcohol Dependence
- Ethical Issues in Publishing Addiction Science
Chair: Thomas F. Babor, Associate Editor, Addiction
- Treating Addiction During Pregnancy: Exploring Multinational Perspectives to Build a Treatment Approach Consensus
- Poster Session

There is no registration fee to attend the 2009 NIDA International Forum. However, pre-registration is required. Because both the NIDA International Forum and the CPDD meetings have their own registration and abstract submission processes, two separate transactions are required to register for both these meetings.

[Forum Online Registration](http://international.drugabuse.gov/information/intl_forum_2009.html)

Meeting programs and other information is also available at
http://international.drugabuse.gov/information/intl_forum_2009.html

Congratulations!

Anna Rose Childress, Ph.D.
is our new President-Elect

Sandra Comer, Ph.D.
Leonard Howell, Ph.D.
Lawrence S. Brown, Jr.,
M.D., M.P.H.

and
Scott E. Lukas, Ph.D. will
join the Board of Directors.

See you in Reno!



Meeting Highlights – The 2008 J. Michael Morrison Award

As a memorial to this well-liked and respected administrator at NIDA, an award is given every other year for outstanding contributions in the area of scientific administration related to drugs of abuse.

2008 Awardees: Rita Liu, Ph.D. and Betty Tai, Ph.D.

Dr. Rita Liu is the NIDA Referral Officer and the Referral Liaison to the NIH Center for Scientific Review. She serves as Scientific Review Officer for the NIDA Centers Review Committee and also for applications responding to RFAs. She co-chairs the NIDA Neuroscience Consortium Working Group that promotes cutting-edge neuroscience and coordinates NIDA activities at the Society for Neuroscience annual meetings. She co-edited the Special Issues of Neuropharmacology in 2004 commemorating NIDA's 30th and, in 2008, the 35th anniversaries. Prior to joining NIDA in 1988, she held faculty positions in Georgetown University and Uniformed Services University of the Health Sciences. She was trained as a dentist in the National Taiwan University Medical College and received a M.S. in Oral Pathology and Anatomy from Emory University. While working in the Neuroanatomy laboratory of Dr. Muriel Ross at the University of Michigan, she decided to pursue research in neuroscience and obtained a Ph.D. from Georgetown University. Dr. Liu was a NIDA R01 recipient in pain research before she was recruited as the SRA for the NIDA Biochemistry Research Committee, later renamed NIDA-B. She has received numerous honors from NIDA and NIH.

Dr. Tai received her M.S. from the University of Massachusetts, her Ph.D. from the George Washington University, and her post-doctoral training from the

laboratory of neuroscience at NIA. Her doctoral and post-doctoral research focused on the kinetic properties of electrolytes and weak electrolytes transport across epithelia and blood brain barrier. This experience guided her interests toward the application of pharmacokinetics and pharmacodynamics to drug development. After a tour of duty at FDA as a clinical pharmacology reviewer, she returned to NIDA in 1989 and became an extramural program administrator directing clinical research programs for the development of anti-drug abuse medications. Since her appointment in 1999, Dr. Tai has served as the Director of NIDA's Clinical Trials Network (CTN) Program. The CTN Program is intended to bridge the gap between research and practice, rapidly translate research to practice, and raise the drug abuse treatment standard across the nation using science as the vehicle. Dr. Tai has received several awards including Research Service Awards from the Board of Scientific Affairs of the American Psychological Association and the Outstanding Public Service Award from the Chinese National Institute on Drug Dependence - National Peking University.

Introduction by Martin Adler, Ph.D.

I have the great privilege and honor to introduce our 2 recipients of the J. Michael Morrison Award. I was fortunate to have known and worked with Michael Morrison for a few years prior to his very untimely death at the age of 36. Mike was an administrator at NIDA in the position known as Executive Secretary of a Study Section, now known as Scientific Review Administrator (SRA). When Mike died, I helped establish this award to honor his memory. He was an exemplary person in many ways. He always found a way to pick the most appropriate reviewers for a



Rita Liu (center) receives The J. Michael Morrison Award from Martin Adler (right) and CPDD President Stephen Higgins (left).

Michael Morrison Award *continued from page 4*

grant application and to go on site visits at a time when we had such things. His overriding aims were to insure a proper review of an application and to insure that the pink sheet (summary statement) was an accurate reflection of the review and the discussion. He would use very innovative ways of achieving that goal.

Having 2 winners of the award is highly unusual, but so are the recipients. Both exemplify the attributes that we admired so much in Michael Morrison. My remarks are based on my knowledge of the winners and on the outstanding letters of nomination that were received on their behalf. Drs. Liu and Tai are tied together not only by their exceptional work at NIDA, but I found out last night that they attended the same high school and the same college in Taiwan.

Introduction of Rita Liu by Martin Adler, Ph.D.

Taken in alphabetical order, the first recipient is Dr. Rita Liu.

Rita joined NIDA in 1988, so she and I have known each other for 20 years. She received her DDS from National Taiwan University, then an MS in Anatomy and Oral Pathology from Emory University in 1966 and a PhD in Neuroanatomy from Georgetown University in 1979. Before coming to NIDA, Dr. Liu had a productive publication record and consistent grant support, including a grant from NIDA.

Dr. Liu was the SRA of the NIDA-B subcommittee for almost 10 years. In 1998, she became the SRA of the newly formed Centers Review Committee and I was fortunate to chair that committee. She also organizes special emphasis panels, and she has conducted hundreds of review meetings, dozens of site visits for research applications and centers and completed thousands of summary statements.

As if that isn't enough work, Dr. Liu is the NIDA Referral Officer. Another

important function that Dr. Liu performs is that of Referral Liaison. She works closely with CSR for resolving dispute of assignments with other NIH institutes and centers. Her dedication to fairness is a hallmark of Dr. Liu's many other good characteristics.

Dr. Liu has also served as the NIDA Neuroscience Consortium Co-chair for many years, and has promoted NIDA's interest in many ways, including organizing NIDA Mini-conventions on "Frontiers in Addiction Research" at the Annual Meeting of the Society for Neuroscience and offering training to young investigators at CPDD meetings.

I could easily spend a half-hour talking about her accomplishments. Dr. Liu has received numerous awards of merit and appreciation. She is an exemplary scientific administrator and dedicated public servant. Dr. Liu truly represents the high quality of service and efficiency that NIDA has come to represent. She cares deeply about the science of drug abuse and the investigators who produce that science.

Rita is highly professional and she very carefully instructs both applicants and reviewers in the rules of clear but respectful discourse, while she herself models that behavior. For Rita Liu, what she does is a labor of love.

Let me conclude by saying that Dr. Liu has always demonstrated a natural ability for the work, as well as a sincere interest and concern for all those she serves, but most especially for the grantees. In addition, her tireless dedication to advancing the course of drug abuse science has inspired many.

It is with the greatest pleasure that we at CPDD present the 2008 J. Michael Morrison Award to Dr. Rita Liu.

Acceptance Remarks by Dr. Liu

Thank you, Dr. Marty Adler, for this most wonderful introduction. I am deeply

Continued on page 7



Rita Liu

J. Michael Morrison Award *continued from page 5*

honored for receiving and sharing this prestigious Award with Dr. Betty Tai. I would like to thank the Award Committee for selecting me for there are a lot of deserving persons in NIDA: I am surrounded by dedicated and hard working colleagues in my office and in every other office and division. I still can't believe my good fortune that I am actually holding this award. To me this award is more precious than winning the Oscar. This is because by making movies, you either make your audience happy or make your audience happier, while by reviewing applications, I routinely make a great many applicants unhappy. So, for my being recognized for this Award, Mike Morrison was known as the most-liked scientific administrator, is something I would not have dreamed of. I am a lucky person indeed.

Since the day I joined NIDA I have many distinguished scientists as study section chairs, they are Horace Loh, Bill Dewey, Nancy Lee, Susan Amara, Bertha Madras, Phil Costanzo and the late Billy Martin. I also have the support from many distinguished CPDD members on review panels like Glen Hanson, Tom Crowley, Marty Adler, Steve Childers, Ivy Carroll, Kathy Carroll, Kathy Cunningham, Steve Higgins, Chuck O'Brien, Chris Evans, Martin Iguchi, Jim Gibb, Mike Bardo, Bob Malcolm, Sherry Deren, Maarten Reith and many, many more. You are there for me when I need you. I am very grateful for that. Thank you all.

Introduction of Betty Tai by Martin Adler, Ph.D.

Dr. Betty Tai joined NIDA in 1989, and I was fortunate to have met her shortly after that. After receiving her M.S. from the University of Massachusetts, her Ph.D. from George Washington University, doing a post-doctoral stint in neuroscience at NIA, and a tour at the FDA, Betty joined NIDA directing clinical research programs in the Medications

Development Division. She has served as the Director of NIDA's Clinical Trials Network since its inception in 1999. She has received several awards, including a Research Service Award from the American Psychological Association.

The objective of the CTN was to identify promising evidence-based treatments, to conduct clinical trials testing their effectiveness when delivered by community-based practitioners to their patients, and then, for those found to be effective, developing training packages to promote the widespread adoption of the new treatments into community-based practice.

Dr. Tai has carefully fostered the linkages between researchers and clinicians. Both scientists and community-based clinicians have come to trust her, to respect her dedication and hard work, and to look to her leadership. She has thus placed herself, and the CTN and NIDA, at the nexus between scientific and clinical leaders in the addiction field, creating an interchange that has moved both science and treatment forward and will continue to do so in the years to come.

Her work has involved coordination of the activities of each of the Nodes and organization and management of NIDA staff overseeing these activities. Her leadership has been both administrative and scientific, as she has led CTN participants to consensus regarding what studies to pursue and with what designs. She has led the CTN through significant transitions to better carry out the mission, and changes in the leadership and priorities of NIDA itself. No one in CTN works harder or cares more than Dr. Tai, and this quality of her leadership has set the pace and made this major NIDA initiative a success. CTN is having a lasting impact by promoting the role of science and evidence in the delivery of care to addicted patients throughout the



Betty Tai (center) receives The J. Michael Morrison Award from Martin Adler (right) and CPDD President Stephen Higgins (left).

Continued on page 8

J. Michael Morrison Award *continued from page 7*

U.S., and much of this success can, in the end, be attributed to Dr. Tai's leadership.

Dr. Tai works tirelessly on behalf of the CTN and has helped bring together the research and treatment community, as well as researchers with a wide variety of different interests, to develop a wide-ranging series of multi-site studies in the CTN. She works very hard behind the scenes to try to ensure the success of the CTN.

Although I have not been involved directly in the CTN program, our paths often cross. Recently, I was gathering information about the relatively new CTSA program. I called Betty for information. Without my asking, she set up a meeting for me and a colleague with the NIH people that lasted for at least 2 hours and provided valuable information and insight. Betty was there for the entire meeting making suggestions and guiding us. This is typical of her dedication to NIDA and to the field.

CPDD proudly presents the 2008 J. Michael Morrison Award to Dr. Betty Tai.

Acceptance Remarks by Dr. Tai

Twenty-four years ago, pregnant with my second child, I reluctantly left laboratory bench work and moved into extramural science administration. Little did I know, it would turn out to be a wonderful and rewarding career path.

I joined NIDA in 1989 and have

worked in several different programs in the applied clinical research areas. These assignments provided me with opportunities to meet and interact with leading scientists in the drug abuse field, to witness their research advances and to watch their careers flourish. They also afforded me an unparalleled view of the broad landscape of NIDA's research portfolio and allowed me to appreciate the challenges of translating basic research discoveries into practical benefits in patient care. In the past eight-and-a-half years, through the NIDA Clinical Trials Network program, I have met and worked with many front-line addiction treatment clinicians. I have been moved and humbled by their compassion and dedication to serve the most devastated patient populations under the most deprived conditions. This experience has not only furthered my commitment to NIDA's mission, it has also strengthened my belief in it.

I am thrilled and honored to have been acknowledged by the CPDD with the prestigious J. Michael Morrison Award. However, a program officer cannot achieve program success alone, so this award belongs to not just me but all of my colleagues inside and outside of NIDA. As much as we should be proud of our accomplishments, we should all also be mindful that there still remains much to be done.



Betty Tai

Airport Shuttle

No need to get a taxi or shuttle from the Reno airport! John Ascuaga's Nugget Hotel provides an airport shuttle service. The airport shuttle runs every 30 minutes, picking up at the airport 15 minutes before the hour and 15 minutes after the hour. The service runs from 4:30 AM to 12 Midnight and can be found outside door "D" past the baggage claim area. When returning to the airport from the hotel, the

shuttle departs from the Valet parking area every 30 min, on the hour and half-hour. For maps of pickup locations and other information, go to the hotel website: <http://www.janugget.com/hotel/shuttle.cfm>

Also, for those planning on renting a car, it is cheaper to rent at the hotel than at the airport, due to airport taxes.

2009 Meeting of the International Study Group Investigating Drugs As Reinforcers (ISGIDAR)

8:30 a.m. - 5:00 p.m. Saturday, June 20, 2009
John Ascuaga's Nugget Resort, Reno/Sparks, Nevada

List of Speakers

Angela N. Duke, *Effects of baclofen on alcohol seeking and consumption under a chained schedule of reinforcement in baboons*

Richard A. Meisch, *Effects of d-amphetamine pretreatment on cocaine-seeking behavior maintained under an interlocking schedule*

Morgane Thomsen, *Selective muscarinic receptor ligands as targets for cocaine addiction medication*

James H. Woods, *Choice procedures and the aversive effects of drugs in rats: preliminary findings*

William E. Fantegrossi, *Tweaking the assay: are our self-administration methods sufficient to detect reinforcing effects of hallucinogen-like drugs in laboratory animals?*

Francesco Leri, *Place conditioning in rats: the difficulties of a simple procedure*

Richard De La Garza, *When subjective and reinforcing effects data don't coincide - What does it mean, and are some data always more meaningful than others?*

Best Student Paper Winner: Justin J. Anker, *Progesterone metabolite, allopregnanolone, attenuates cocaine-seeking behavior in female rats*

Kenneth Perkins, *No reinforcement enhancing effects of nicotine in humans*

Mark Greenwald, *Behavioral pharmacogenetic analysis of opioid seeking behavior*

Kenneth Grasing, *Selective breeding for differences in cocaine self-administration*

Thomas A. Green, *Mechanisms of environmental enrichment-mediated decreases in self-administration of cocaine and amphetamine*

Jennifer Newman, *Effects of chronic modafinil on methamphetamine self-administration*

Fei Shen, *The critical role of hippocampal neurotrophic factor trkb and glutamatergic NMDA receptors in amphetamine reward-mediated behavior*

Breakfast & Registration (\$80) at the door at 8:30; talks at 9:00 a.m.
For further information, contact Dr. Elise Weerts (eweerts@jhmi.edu)

The annual scientific meeting... serves as a forum for scholarly exchange among preclinical and clinical investigators from academia, government, the pharmaceutical industry, and colleagues in government regulatory and policy-making positions.

Book Review

Discovering Addiction: The Science and Politics of Substance Abuse Research

**by: Nancy D. Campbell
2007 The University of Michigan Press, 301 pages.**

Review by Jack E. Henningfield
The Johns Hopkins University School of Medicine and Pinney Associates

“Discovering Addiction” is an insider’s story of the Lexington Narcotic Farm, later named the Addiction Research Center (ARC). The sources include more than 60 interviews and innumerable published and archival documents including meeting minutes and personal accounts of drug addiction researchers. Many of the researchers are past and present CPDD members. This is a great story, but also a first rate documentary written by a historian, Nancy, D. Campbell, Ph.D., who is Associate Professor in the Department of Science and Technology Studies of Rensselaer Polytechnic Institute. She has written a fascinating account of the emergence and evolution of the ARC. It is also implicitly an account of the emergence and early evolution of CPDD because the history of the ARC is inextricably intertwined with the history and even many organizational aspects of CPDD. In turn, this is a history of the evolution of the concept of addiction itself. It is a must-read for CPDD members because it is our history. CPDD members will find reading it much as though they had suddenly discovered an insightful history of their own family history with lots of eye-opening details and personal insights that help explain the hows and the whys of today.

Many may be surprised at how many links they have with the ARC through mentors and colleagues. Just as nearly all roads in behavioral pharmacology lead to Joe Brady, so do many roads in addiction

related science lead to the ARC. Discovering the intricate intertwining, and sometimes clashing, relationships in the field are engaging and make the book hard to set aside. The numerous and often colorful quotes of pioneers past and present give this book warmth, reality, and relevance to where we have come from, where we are, and insights on where we are going as a field, and for CPDD, as a scientific organization.

Long-term members who have lived through changes in name and affiliation of the College from its early days as the Committee on Drug Addiction (CDAN from 1928-1965) and Committee on Problems of Drug Dependence (from 1966 to 1990) will appreciate reading this account of history of which they were a part. Newer members are sure to be fascinated by the many challenges, scientific, ethical, and political, that needed to be surmounted to “discover” the scientific foundation for addiction. Many will be surprised by how much of the College’s current activities and standing committees go back decades to the core initial goals of the College. These included the search for nonaddicting analgesics, assessing the abuse potential of novel chemical entities, and developing methods for scientifically valid and ethical human and animal research – activities that to this day remain challenges for CPDD researchers and are exemplified by presentations at the annual meeting of the College.

Nancy Campbell developed this book over 5 years of research during which she investigated the history of our field through the literature, through archival digging, reviews of various historical records and personal histories and her own recorded interviews, many of which are posted at the University of Michigan Substance Abuse Research Center Website (see:

CPDD has been in existence since 1929 and is the longest standing group in the United States concerned with research on problems of drug dependence

Continued on page 11

Book Review *continued from page 10*

http://sitemaker.umich.edu/substance_abuse.history/oral_history_interviews).

She uncovered a treasure-trove of facts, pictures, videos, and insights, including a 1964 photographic archive of the Michigan primate laboratory and the Addiction Research Center taken by former Life Magazine photographer, Bill Eppridge. Many CPDD members have already seen some of these works at the Robert Wood Johnson Foundation, Innovators Awards Program Addiction Art galleries at CPDD, and several are presented in "Discovering Addiction". As a scientist who has done some work with nicotine, I love the shot of a Michigan laboratory technician smoking a cigarette with a monkey perched on his back.

One of the several stories running through the book was the challenge of determining which human populations would provide the most valid and generalizable data in experiments that would be considered ethical – at least at the time. More than half a century ago, as today, these questions were as important as the scientific hypotheses that such research was intended to resolve. Then, as today, there were differences of opinion as to what populations could be tested and under what conditions, and then as today, research leaders clearly took the bioethical questions as seriously as the scientific questions. Wikler, Isbell and other ARC researchers felt that well experienced former drug abusers were the only population that could ethically be given many of the drugs under the conditions necessary to explore their addictive effects. On the other hand, Beecher, at the Harvard Anesthesiology Laboratory, known as the "father of informed consent", felt that people with addiction histories would yield atypical responses of little generality to the larger population.

Clinical researchers of today will

surely appreciate the bioethical travails of these pioneers who were trying to do the best research and do it right, but without guidance such as flowed from the Belmont Report on the Protection of Human Research Subject, or from today's Institutional Review Boards. Nonetheless, *Discovering Addiction* gave me a heightened appreciation for the degree to which their research approaches embodied the three key principles of the Belmont Report, namely, *respect for persons, beneficence, and justice*. Nonetheless, when science, bioethics and political aspirations collided in the 1970s, political aspirations won, and the Addiction Research Center's clinical research program at Lexington ground quickly to a halt. Fortunately, it reemerged on the Johns Hopkins Bayview Campus in Baltimore where researchers learned to safely and ethically conduct valid research with a non-prisoner population.

Nancy Campbell uses the words of Himmelsbach, Wikler and many others to show the reader how scales came to be developed to measure withdrawal, and the time course of drug effects. We learn how the hallmark construct of addictive drug effects, "euphoria," was as controversial then as now for what it was, how to measure it, and what findings about euphoria meant. We see controversies that remain today over the importance of personality and individuality versus environmental conditions in the development of addiction. As new technology-enabled research approaches emerge from molecular genetics and cerebral imaging, the phenomena of the human experience associated with the reinforcing effects of drugs and addiction remains among the most challenging to capture and quantify. I suspect that Isbell, Wikler, Himmelsbach, Frazier, and the many other pioneers of the ARC would tell us not to forget to spend time observing

CPDD membership includes a subscription to Drug and Alcohol Dependence, which is ranked among the most cited substance abuse research journals.

Continued on page 13



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Substance Abuse Treatment

Center for Substance Abuse Treatment Satellite Session

Implementing Evidence-Based Practices for Adolescent Treatment

June 20, 2009

Sparks, NV

Special Full-Day Event Preceding the CPDD Annual Meeting
Saturday, June 20, 2009
9:00 Am - 5:30 PM
John Ascuaga's Nugget Resort, Reno/Sparks, Nevada

Conference Features

- Keynote presentation by Dr. H. Westley Clark, Director, Center for Substance Abuse Treatment
- Panel discussions with prominent speakers in the field including:
 - Susan H. Godley, Rh.D., Director, Community Reinforcement Approach, Chestnut Health Systems
 - Randy Muck, M.Ed. Chief, Targeted Populations Branch Center for Substance Abuse Treatment
 - Geetha Subramaniam, M.D., Assistant Professor, Pharmacotherapy and Youth, Johns Hopkins School of Medicine
 - Rigoberto Contreras, A-CRA Clinical Supervisor Sin Puertas Program
 - Heather C. Harlan, Director, Project Apex, Phoenix Programs, Inc.
 - Bridget Ruiz, M.Ed., Associate Research Professor Southwest Institute for Research on Women
 - Michael L. Dennis, Ph.D., Senior Research Psychologist Chestnut Health Systems

For information: <http://conferences.jbsinternational.com/cpdd/>

To register: <http://conferences.jbsinternational.com/cpdd/register.php>
CEUs will be available.

For further information contact:

Cathy Crowley
JBS International, Inc.
(240) 645-4142
ccrowley@jbsinternational.com

...AIDS and other infectious diseases such as hepatitis C are national disease challenges that are increasingly prevalent in substance abusers...

CPDD OFFICERS

SHARON L. WALSH, PHD
PRESIDENT

LINDA J. PORRINO, PHD
PRESIDENT-ELECT

STEPHEN T. HIGGINS, PHD
PAST-PRESIDENT

STEPHEN G. HOLTZMAN, PHD
TREASURER

MARTIN W. ADLER, PHD
EXECUTIVE OFFICER

BOARD OF DIRECTORS

PATRICK M. BEARDSLEY, PHD

STEVEN R. CHILDERS, PHD

THEODORE J. CICERO, PHD

RICHARD DE LA GARZA II, PHD

TOBY K. EISENSTEIN, PHD

DAVID A. FIELLIN, MD

A. THOMAS MCLELLAN, PHD

GEOFFREY K. MUMFORD, PHD

MICHAEL A. NADER, PHD

EDWARD V. NUNES, MD

ALISON OLIVETO-BEAUDOIN, PHD

RICHARD A. RAWSON, PHD

MAXINE L. STITZER, PHD

ERIC C. STRAIN, MD

DACE S. SVIKIS, PHD

MICHAEL B. GATCH, PHD, EDITOR

CPDD PUBLICATIONS COMMITTEE

RICHARD DE LA GARZA II, PHD, CHAIR

KATHLEEN M. CARROLL, PHD

RONALD COWAN, MD, PHD

STEPHEN MAGURA, PHD

ROBERT MALISON, MD

JOHN R. MANTSCH, PHD

GREGORY MILLER, PHD

JOHN ROACHE, PHD

LI-TZY WU, ScD

Send materials for NEWSLINE to:

Michael B. Gatch, PhD
U. of North Texas Health Science Center
Pharmacology & Neuroscience
3500 Camp Bowie Boulevard
Fort Worth, TX 76107

Phone (817) 735-2062
Fax (817) 735-0408
Email:mgatch@hsc.unt.edu

Book Review *continued from page 11*

and communicating with drug users to keep in perspective the phenomena that we hope that research will be increasingly able to explain, to be more creative in our approaches to measure such

experience, and in turn to determine which measures provide the greatest generality and predictability beyond the laboratory.

Editor's Notes

This issue includes a review of Nancy Campbell's book "Discovering Addiction: The Science and Politics of Substance Abuse Research". The book was suggested by Jack Henningfield, who graciously agreed to review it. The timing of his submission was fortuitous, as Nancy Campbell will be awarded the CPDD/NIDA Media Award this year. She will be recognized for her body of work in the addiction area, including her books "Using Women: Gender, Drug Policy, and Social Justice", "Discovering Addiction" and for her contributions to the "The Narcotic Farm", as well as numerous articles and presentations. Hopefully, the review will encourage CPDD members to read "Discovering Addiction" as well as her other books. As I mentioned a year ago, there is no other venue for reviews of books on addiction. There are many wonderful books out there, but few of us have the time or resources to even notice them all. If you find an exceptional book on substance use, abuse or addiction, please don't assume others have seen it—share it.

Another issue of general interest is the discussion about a merger between the NIAAA and NIDA, which Sharon Walsh mentioned in her presidential column in this issue. For those interested in more detail, a videocast of the advisory board

meeting is available at:

<http://videocast.nih.gov/launch.asp?15063> . Please note that the viewer will launch in its own window, and that the video is 450 min long.

Finally, Richard De La Garza, II, Ph.D. is stepping down as chair of the Publications Committee as he rotates off the committee. Rich has been instrumental in providing high quality content for the News & Views section in Drug and Alcohol Dependence, the CPDD-sponsored journal. He also encouraged expanded content in CPDD Newsline, including publication of CPDD Award presentations, interviews of Nathan Eddy Award winners as Voices of Experience, and book reviews. These articles were intended to expand awareness of history, current events and resources for learning more about substance use, abuse, and addiction, and to encourage and motivate young researchers. Rich is still contributing to CPDD, as he is serving a term on the Board of Directors. I would also like to extend a welcome to Gregory Miller, Ph.D., who will take over as chair of the Publications Committee in June.

To close, a couple of tips for Reno. It may be June in Nevada, but the elevation is 4000 feet, so temperatures at night can drop into the 40s. Bring a jacket and remember to drink plenty of fluids. See you in Reno!

-- Contributed by Michael B. Gatch, Ph.D.

Editor, Newsline